FY2025 EPS Estimate for Entera Bio Increased by Analyst

Entera Bio Ltd. (NASDAQ:ENTX) – Research analysts at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for Entera Bio in a note issued to investors on Tuesday, December 23rd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.28) for the year, up from their prior forecast of ($0.32). The consensus estimate for Entera Bio’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Entera Bio’s Q4 2025 earnings at ($0.09) EPS, Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.21) EPS and FY2026 earnings at ($0.68) EPS.

A number of other equities analysts also recently weighed in on ENTX. Wall Street Zen raised shares of Entera Bio to a “sell” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Entera Bio in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Entera Bio currently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Entera Bio Stock Performance

Shares of NASDAQ ENTX opened at $1.72 on Thursday. The company’s 50 day moving average price is $2.39 and its 200-day moving average price is $2.12. Entera Bio has a 52-week low of $1.50 and a 52-week high of $3.22. The company has a market capitalization of $78.88 million, a P/E ratio of -6.88 and a beta of 1.71.

Entera Bio (NASDAQ:ENTX) last released its earnings results on Friday, November 14th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. Entera Bio had a negative net margin of 4,525.11% and a negative return on equity of 67.56%.

Institutional Investors Weigh In On Entera Bio

Large investors have recently bought and sold shares of the stock. HighTower Advisors LLC increased its stake in Entera Bio by 53.3% in the first quarter. HighTower Advisors LLC now owns 18,140 shares of the company’s stock valued at $31,000 after purchasing an additional 6,310 shares in the last quarter. Parkman Healthcare Partners LLC boosted its position in shares of Entera Bio by 6.3% during the 1st quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company’s stock worth $747,000 after purchasing an additional 25,900 shares in the last quarter. Citadel Advisors LLC grew its stake in shares of Entera Bio by 243.0% in the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after buying an additional 28,322 shares during the period. Finally, Bessemer Group Inc. bought a new stake in Entera Bio in the 2nd quarter valued at about $268,000. 14.11% of the stock is currently owned by institutional investors and hedge funds.

About Entera Bio

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.